JP5079818B2 - Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 - Google Patents
Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 Download PDFInfo
- Publication number
- JP5079818B2 JP5079818B2 JP2009542835A JP2009542835A JP5079818B2 JP 5079818 B2 JP5079818 B2 JP 5079818B2 JP 2009542835 A JP2009542835 A JP 2009542835A JP 2009542835 A JP2009542835 A JP 2009542835A JP 5079818 B2 JP5079818 B2 JP 5079818B2
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- nhso
- compound
- aryl
- heteroaryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 0 *c1cc(cc[n]2)c2nc1 Chemical compound *c1cc(cc[n]2)c2nc1 0.000 description 61
- FLKBNILXXMIRFX-UHFFFAOYSA-N CC(C(C)=CN1)=CC1=O Chemical compound CC(C(C)=CN1)=CC1=O FLKBNILXXMIRFX-UHFFFAOYSA-N 0.000 description 3
- MVKDNXIKAWKCCS-UHFFFAOYSA-N CC1=CC=CNC1=O Chemical compound CC1=CC=CNC1=O MVKDNXIKAWKCCS-UHFFFAOYSA-N 0.000 description 3
- FTZFIWWLBDDFGF-UHFFFAOYSA-N CC(C(F)=CN1)=CC1=O Chemical compound CC(C(F)=CN1)=CC1=O FTZFIWWLBDDFGF-UHFFFAOYSA-N 0.000 description 2
- YBDRFJXGJQULGH-UHFFFAOYSA-N CC(C=CN1)=CC1=O Chemical compound CC(C=CN1)=CC1=O YBDRFJXGJQULGH-UHFFFAOYSA-N 0.000 description 2
- JFONHTQRVUGNKX-UHFFFAOYSA-N Cc(c(F)c1)cc2c1[nH]cn2 Chemical compound Cc(c(F)c1)cc2c1[nH]cn2 JFONHTQRVUGNKX-UHFFFAOYSA-N 0.000 description 2
- XLAFKBXUNAYWQC-UHFFFAOYSA-N Cc(c(F)c1)cc2c1[nH]nc2N Chemical compound Cc(c(F)c1)cc2c1[nH]nc2N XLAFKBXUNAYWQC-UHFFFAOYSA-N 0.000 description 2
- CTCHXZUMFHNSHM-UHFFFAOYSA-N Cc(cc1)cc(N2)c1NC2=O Chemical compound Cc(cc1)cc(N2)c1NC2=O CTCHXZUMFHNSHM-UHFFFAOYSA-N 0.000 description 2
- MMESFNIBUITFJA-UHFFFAOYSA-N Bc(cc(C)c(F)c1)c1N Chemical compound Bc(cc(C)c(F)c1)c1N MMESFNIBUITFJA-UHFFFAOYSA-N 0.000 description 1
- ULENLWHUYLORAM-UHFFFAOYSA-N BrC1C2SC=CC2=CCC1 Chemical compound BrC1C2SC=CC2=CCC1 ULENLWHUYLORAM-UHFFFAOYSA-N 0.000 description 1
- DSIWLDCXHHMNQL-UHFFFAOYSA-N C=Cc(cc(cc1)F)c1F Chemical compound C=Cc(cc(cc1)F)c1F DSIWLDCXHHMNQL-UHFFFAOYSA-N 0.000 description 1
- IMJOYKXJXWTJER-UHFFFAOYSA-N C=NCC1=NC=NC2=CNC=CN12 Chemical compound C=NCC1=NC=NC2=CNC=CN12 IMJOYKXJXWTJER-UHFFFAOYSA-N 0.000 description 1
- HEJZAMYPXNFFGK-UHFFFAOYSA-N C=Nc1ccnc2c1nc[nH]2 Chemical compound C=Nc1ccnc2c1nc[nH]2 HEJZAMYPXNFFGK-UHFFFAOYSA-N 0.000 description 1
- ZHCBOOHHPIGJGQ-UHFFFAOYSA-N CC(C)(C)OC(N(C1O)C=Nc2c1cc(C)c(F)c2)=O Chemical compound CC(C)(C)OC(N(C1O)C=Nc2c1cc(C)c(F)c2)=O ZHCBOOHHPIGJGQ-UHFFFAOYSA-N 0.000 description 1
- DRCXMSKSPGCLBQ-UHFFFAOYSA-N CC(C)C1=CC=NC2=CNC=CN12 Chemical compound CC(C)C1=CC=NC2=CNC=CN12 DRCXMSKSPGCLBQ-UHFFFAOYSA-N 0.000 description 1
- AZHDLAADBXXPAS-UHFFFAOYSA-N CC(C)c1cc(C=C)c(NC=C)nc1 Chemical compound CC(C)c1cc(C=C)c(NC=C)nc1 AZHDLAADBXXPAS-UHFFFAOYSA-N 0.000 description 1
- WWRCMNKATXZARA-UHFFFAOYSA-N CC(C)c1ccccc1C Chemical compound CC(C)c1ccccc1C WWRCMNKATXZARA-UHFFFAOYSA-N 0.000 description 1
- GNZXIZXIMJXQIS-UHFFFAOYSA-N CC(C)c1ccnc(N)c1 Chemical compound CC(C)c1ccnc(N)c1 GNZXIZXIMJXQIS-UHFFFAOYSA-N 0.000 description 1
- LAUUYGYGJLFJGT-UHFFFAOYSA-N CC(C1C)C2=C1OCN2 Chemical compound CC(C1C)C2=C1OCN2 LAUUYGYGJLFJGT-UHFFFAOYSA-N 0.000 description 1
- ZZYKYYGUTNDPQE-UHFFFAOYSA-N CC(C1C)C2=C1SCN2 Chemical compound CC(C1C)C2=C1SCN2 ZZYKYYGUTNDPQE-UHFFFAOYSA-N 0.000 description 1
- NYSUZLLUWLMTCO-UHFFFAOYSA-N CC(C1C)c2c1[o]cn2 Chemical compound CC(C1C)c2c1[o]cn2 NYSUZLLUWLMTCO-UHFFFAOYSA-N 0.000 description 1
- KKMMQNIVOJOQFJ-UHFFFAOYSA-N CC(C1C)c2c1nc[nH]2 Chemical compound CC(C1C)c2c1nc[nH]2 KKMMQNIVOJOQFJ-UHFFFAOYSA-N 0.000 description 1
- BCBPIZWEWHKVDQ-UHFFFAOYSA-N CC(C1C)c2c1nn[nH]2 Chemical compound CC(C1C)c2c1nn[nH]2 BCBPIZWEWHKVDQ-UHFFFAOYSA-N 0.000 description 1
- LSTQTJVLENRHOC-UHFFFAOYSA-N CC(c(cccc1)c1N)SC Chemical compound CC(c(cccc1)c1N)SC LSTQTJVLENRHOC-UHFFFAOYSA-N 0.000 description 1
- VZZJXQBDOKUWJA-UHFFFAOYSA-N CC(c1cccc2c1nc[nH]2)=C Chemical compound CC(c1cccc2c1nc[nH]2)=C VZZJXQBDOKUWJA-UHFFFAOYSA-N 0.000 description 1
- FMLFRMWXGHLDCE-UHFFFAOYSA-N CC(c1ccnc2c1ccnn2)=C Chemical compound CC(c1ccnc2c1ccnn2)=C FMLFRMWXGHLDCE-UHFFFAOYSA-N 0.000 description 1
- MIDXGVUKRKCDCS-UHFFFAOYSA-N CC1(C)c(ccc2c3c(-c(cccn4)c4OC4=O)c4[n]2Cc2cc4ccccc4nc2Cl)c3OC1 Chemical compound CC1(C)c(ccc2c3c(-c(cccn4)c4OC4=O)c4[n]2Cc2cc4ccccc4nc2Cl)c3OC1 MIDXGVUKRKCDCS-UHFFFAOYSA-N 0.000 description 1
- PPRQBIRLFNSEAU-ASXYILGKSA-N CC1(C)c(ccc2c3c(/C(/C(N)=O)=C/C=C\C)c(C(O)O)[n]2Cc2cc4ccccc4nc2Cl)c3OC1 Chemical compound CC1(C)c(ccc2c3c(/C(/C(N)=O)=C/C=C\C)c(C(O)O)[n]2Cc2cc4ccccc4nc2Cl)c3OC1 PPRQBIRLFNSEAU-ASXYILGKSA-N 0.000 description 1
- GISZIMZJUWRYIR-UHFFFAOYSA-N CC1=CC2NC=NC2CC1F Chemical compound CC1=CC2NC=NC2CC1F GISZIMZJUWRYIR-UHFFFAOYSA-N 0.000 description 1
- ODOVRBRKOVVHFS-UHFFFAOYSA-N CC1=CC=NC2=CNC=CN12 Chemical compound CC1=CC=NC2=CNC=CN12 ODOVRBRKOVVHFS-UHFFFAOYSA-N 0.000 description 1
- UARNRWLLDSQSBB-UHFFFAOYSA-N CCC(C)Cc(cc(cc1)Cl)c1Cl Chemical compound CCC(C)Cc(cc(cc1)Cl)c1Cl UARNRWLLDSQSBB-UHFFFAOYSA-N 0.000 description 1
- PTMVFRKAMOUORT-UHFFFAOYSA-N CCc(c(N)c1)ccc1N Chemical compound CCc(c(N)c1)ccc1N PTMVFRKAMOUORT-UHFFFAOYSA-N 0.000 description 1
- ZSIMBMYNZHSZGJ-UHFFFAOYSA-N CCc(cc(cc1)N)c1N Chemical compound CCc(cc(cc1)N)c1N ZSIMBMYNZHSZGJ-UHFFFAOYSA-N 0.000 description 1
- MJTYPPBFTMKLGA-UHFFFAOYSA-N CCc(ccc(Cl)c1)c1Cl Chemical compound CCc(ccc(Cl)c1)c1Cl MJTYPPBFTMKLGA-UHFFFAOYSA-N 0.000 description 1
- MEMBJMDZWKVOTB-UHFFFAOYSA-N CCc1ccc(C)cc1C Chemical compound CCc1ccc(C)cc1C MEMBJMDZWKVOTB-UHFFFAOYSA-N 0.000 description 1
- XAWJTNCEMPZPGU-UHFFFAOYSA-N CN(C)CC1=CC=CNC1=O Chemical compound CN(C)CC1=CC=CNC1=O XAWJTNCEMPZPGU-UHFFFAOYSA-N 0.000 description 1
- KPKPQNCSHKTVSF-UHFFFAOYSA-N COC(C(C1)=Cc2c1ccc1c2SCC1)=O Chemical compound COC(C(C1)=Cc2c1ccc1c2SCC1)=O KPKPQNCSHKTVSF-UHFFFAOYSA-N 0.000 description 1
- ALTITKDJJHISFZ-UHFFFAOYSA-N COc(nc1)cc(C[N+]([O-])=O)c1F Chemical compound COc(nc1)cc(C[N+]([O-])=O)c1F ALTITKDJJHISFZ-UHFFFAOYSA-N 0.000 description 1
- SMJGDOBFOCHGEN-UHFFFAOYSA-N CSSc1ccccc1F Chemical compound CSSc1ccccc1F SMJGDOBFOCHGEN-UHFFFAOYSA-N 0.000 description 1
- BCPVIZOAYWVCSF-UHFFFAOYSA-N C[BrH]C(C(CCC1)C1CC1)C1N Chemical compound C[BrH]C(C(CCC1)C1CC1)C1N BCPVIZOAYWVCSF-UHFFFAOYSA-N 0.000 description 1
- WFYJWGYCBGYOIB-JVPSVYLMSA-N C[C@@H](CC=CC=C12)C1=C(C1)C1C1c3c4c2c(C(O)=O)[n](Cc(cc(cc(C)cc2)c2n2)c2O)c4cc(F)c3C=C1 Chemical compound C[C@@H](CC=CC=C12)C1=C(C1)C1C1c3c4c2c(C(O)=O)[n](Cc(cc(cc(C)cc2)c2n2)c2O)c4cc(F)c3C=C1 WFYJWGYCBGYOIB-JVPSVYLMSA-N 0.000 description 1
- RINZXSWBCADDON-UHFFFAOYSA-N Cc([nH]1)cc2c1nccc2CN=C Chemical compound Cc([nH]1)cc2c1nccc2CN=C RINZXSWBCADDON-UHFFFAOYSA-N 0.000 description 1
- FUNUTBJJKQIVSY-UHFFFAOYSA-N Cc(c(Cl)c1)ccc1Cl Chemical compound Cc(c(Cl)c1)ccc1Cl FUNUTBJJKQIVSY-UHFFFAOYSA-N 0.000 description 1
- MPXDAIBTYWGBSL-UHFFFAOYSA-N Cc(c(F)c1)ccc1F Chemical compound Cc(c(F)c1)ccc1F MPXDAIBTYWGBSL-UHFFFAOYSA-N 0.000 description 1
- MGRHBBRSAFPBIN-UHFFFAOYSA-N Cc(c(F)c1)ccc1N Chemical compound Cc(c(F)c1)ccc1N MGRHBBRSAFPBIN-UHFFFAOYSA-N 0.000 description 1
- HGOFGTAFCWLANA-UHFFFAOYSA-N Cc(cc(c(C(F)(F)F)c1)I)c1F Chemical compound Cc(cc(c(C(F)(F)F)c1)I)c1F HGOFGTAFCWLANA-UHFFFAOYSA-N 0.000 description 1
- MWFHUUYNKQVJDU-UHFFFAOYSA-N Cc1c2[s]cnc2ccc1N Chemical compound Cc1c2[s]cnc2ccc1N MWFHUUYNKQVJDU-UHFFFAOYSA-N 0.000 description 1
- UFLPRPRRGZVFHG-UHFFFAOYSA-N Cc1cc(Cl)ccc1C1[IH]C1 Chemical compound Cc1cc(Cl)ccc1C1[IH]C1 UFLPRPRRGZVFHG-UHFFFAOYSA-N 0.000 description 1
- DJCJHFFRHKGOCQ-UHFFFAOYSA-N Cc1cc(cc[nH]2)c2nc1 Chemical compound Cc1cc(cc[nH]2)c2nc1 DJCJHFFRHKGOCQ-UHFFFAOYSA-N 0.000 description 1
- VUUJUMZCZFHRFZ-UHFFFAOYSA-N Cc1cc(cn[nH]2)c2nc1 Chemical compound Cc1cc(cn[nH]2)c2nc1 VUUJUMZCZFHRFZ-UHFFFAOYSA-N 0.000 description 1
- GWHJZXXIDMPWGX-UHFFFAOYSA-N Cc1ccc(C)c(C)c1 Chemical compound Cc1ccc(C)c(C)c1 GWHJZXXIDMPWGX-UHFFFAOYSA-N 0.000 description 1
- IVSZLXZYQVIEFR-UHFFFAOYSA-N Cc1cccc(C)c1 Chemical compound Cc1cccc(C)c1 IVSZLXZYQVIEFR-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N Cc1ccccc1C Chemical compound Cc1ccccc1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- IBSQPLPBRSHTTG-UHFFFAOYSA-N Cc1ccccc1Cl Chemical compound Cc1ccccc1Cl IBSQPLPBRSHTTG-UHFFFAOYSA-N 0.000 description 1
- ORLGLBZRQYOWNA-UHFFFAOYSA-N Cc1ccnc(N)c1 Chemical compound Cc1ccnc(N)c1 ORLGLBZRQYOWNA-UHFFFAOYSA-N 0.000 description 1
- SVSYTDAHZIRUPE-UHFFFAOYSA-N Cc1ccnc2c1ccnn2 Chemical compound Cc1ccnc2c1ccnn2 SVSYTDAHZIRUPE-UHFFFAOYSA-N 0.000 description 1
- CVEAAUAFISZRDR-UHFFFAOYSA-N Cc1ccnc2c1cn[nH]2 Chemical compound Cc1ccnc2c1cn[nH]2 CVEAAUAFISZRDR-UHFFFAOYSA-N 0.000 description 1
- IPWBFGUBXWMIPR-UHFFFAOYSA-N Fc1ccccc1Br Chemical compound Fc1ccccc1Br IPWBFGUBXWMIPR-UHFFFAOYSA-N 0.000 description 1
- VABSWNWVLDBXIF-UHFFFAOYSA-N O=CC1=C2SC=CC2=CCC1 Chemical compound O=CC1=C2SC=CC2=CCC1 VABSWNWVLDBXIF-UHFFFAOYSA-N 0.000 description 1
- GGSURPZCTNVEBJ-UHFFFAOYSA-O [NH3+]c1c(C=N)c(C2CC2)ccc1 Chemical compound [NH3+]c1c(C=N)c(C2CC2)ccc1 GGSURPZCTNVEBJ-UHFFFAOYSA-O 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87687706P | 2006-12-22 | 2006-12-22 | |
| US60/876,877 | 2006-12-22 | ||
| PCT/US2007/025754 WO2008082484A1 (en) | 2006-12-22 | 2007-12-17 | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513490A JP2010513490A (ja) | 2010-04-30 |
| JP2010513490A5 JP2010513490A5 (pt) | 2010-10-14 |
| JP5079818B2 true JP5079818B2 (ja) | 2012-11-21 |
Family
ID=39186835
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542835A Expired - Fee Related JP5079818B2 (ja) | 2006-12-22 | 2007-12-17 | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8557848B2 (pt) |
| EP (1) | EP2064180B1 (pt) |
| JP (1) | JP5079818B2 (pt) |
| KR (1) | KR20090094154A (pt) |
| CN (1) | CN101631773A (pt) |
| AR (1) | AR064428A1 (pt) |
| AU (1) | AU2007339382B2 (pt) |
| BR (1) | BRPI0720625A2 (pt) |
| CA (1) | CA2673249C (pt) |
| CL (1) | CL2007003686A1 (pt) |
| CO (1) | CO6190515A2 (pt) |
| EC (1) | ECSP099447A (pt) |
| MX (1) | MX2009006880A (pt) |
| NO (1) | NO20092742L (pt) |
| PE (1) | PE20081608A1 (pt) |
| RU (1) | RU2009127855A (pt) |
| TW (1) | TW200831496A (pt) |
| WO (1) | WO2008082484A1 (pt) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011524359A (ja) * | 2008-06-13 | 2011-09-01 | シェーリング コーポレイション | ３環式インドール誘導体およびその使用方法 |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110104109A1 (en) * | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| EP2064180B1 (en) | 2006-12-22 | 2016-07-13 | Merck Sharp & Dohme Corp. | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| MX2009006877A (es) | 2006-12-22 | 2009-09-28 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos. |
| EP2064181A1 (en) | 2006-12-22 | 2009-06-03 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| EP2197842B1 (en) * | 2007-08-29 | 2012-05-23 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| CN101842374A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物 |
| AU2008295484B2 (en) * | 2007-08-29 | 2013-09-26 | Merck Sharp & Dohme Llc | Substituted indole derivatives and methods of use thereof |
| US8765757B2 (en) * | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) * | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| EP2334662A1 (en) * | 2008-09-26 | 2011-06-22 | F. Hoffmann-La Roche AG | Pyrine or pyrazine derivatives for treating hcv |
| CN102256968A (zh) | 2008-12-22 | 2011-11-23 | 弗·哈夫曼-拉罗切有限公司 | 杂环抗病毒化合物 |
| EP2403844A1 (en) * | 2009-03-06 | 2012-01-11 | F. Hoffmann-La Roche AG | Heterocyclic antiviral compounds |
| AU2010253791A1 (en) | 2009-05-29 | 2011-11-24 | Merck Sharp & Dohme Corp. | Antiviral compounds composed of three linked Aryl moieties to treat diseases such as Hepatitis C |
| WO2011000566A2 (en) * | 2009-06-30 | 2011-01-06 | Savira Pharmaceuticals Gmbh | Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections |
| WO2011066241A1 (en) | 2009-11-25 | 2011-06-03 | Schering Corporation | Fused tricyclic compounds and derivatives thereof useful for the treatment of viral diseases |
| WO2011087740A1 (en) | 2009-12-22 | 2011-07-21 | Schering Corporation | Fused tricyclic compounds and methods of use thereof for the treatment of viral diseases |
| JP2013522202A (ja) | 2010-03-09 | 2013-06-13 | メルク・シャープ・エンド・ドーム・コーポレイション | 縮合三環式シリル化合物およびウイルス疾患の治療のためのその使用方法 |
| EP2598149A4 (en) | 2010-07-26 | 2014-09-10 | Merck Sharp & Dohme | SUBSTITUTED BIPHENYLENE COMPOUNDS AND METHOD FOR USE THEREOF FOR THE TREATMENT OF VIRUS DISEASES |
| WO2012050848A1 (en) | 2010-09-29 | 2012-04-19 | Schering Corporation | Fused tetracycle derivatives and methods of use thereof for the treatment of viral diseases |
| BR112013026345A2 (pt) | 2011-04-13 | 2019-04-24 | Merck Sharp & Dohe Corp. | composto, composição farmacêutica, uso de um composto, e, método para tratar um paciente infectado com hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013033899A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033900A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Tetracyclic heterocycle compounds and methods of use thereof for the treatment of viral diseases |
| WO2013033901A1 (en) | 2011-09-08 | 2013-03-14 | Merck Sharp & Dohme Corp. | Heterocyclic-substituted benzofuran derivatives and methods of use thereof for the treatment of viral diseases |
| WO2013039876A1 (en) | 2011-09-14 | 2013-03-21 | Merck Sharp & Dohme Corp. | Silyl-containing heterocyclic compounds and methods of use thereof for the treatment of viral diseases |
| AR092959A1 (es) | 2012-10-17 | 2015-05-06 | Merck Sharp & Dohme | Derivados de nucleosidos 2-metil sustituidos y metodos de uso de los mismos para el tratamiento de enfermedades virales |
| US9457039B2 (en) | 2012-10-17 | 2016-10-04 | Merck Sharp & Dohme Corp. | 2′-disubstituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2014059901A1 (en) | 2012-10-17 | 2014-04-24 | Merck Sharp & Dohme Corp. | 2'-cyano substituted nucleoside derivatives and methods of use thereof for treatment of viral diseases |
| US9732111B2 (en) | 2012-11-19 | 2017-08-15 | Merck Sharp & Dohme Corp. | 2′-alkynyl substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| WO2014205593A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Substituted benzofuran compounds and methods of use thereof for treatment of viral diseases |
| WO2014205592A1 (en) | 2013-06-24 | 2014-12-31 | Merck Sharp & Dohme Corp. | Heterocyclic compounds and methods of use thereof for treatment of hepatitis c |
| WO2015065817A1 (en) | 2013-10-30 | 2015-05-07 | Merck Sharp & Dohme Corp. | Pseudopolymorphs of an hcv ns5a inhibitor and uses thereof |
| CN106810557B (zh) * | 2015-11-27 | 2021-05-04 | 南京圣和药物研发有限公司 | 杂环化合物及其应用 |
| EP3455219A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | AMINE-RELATED C3-GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| EP4491236A3 (en) | 2016-05-10 | 2025-04-02 | C4 Therapeutics, Inc. | Heterocyclic degronimers for target protein degradation |
| EP3454862B1 (en) | 2016-05-10 | 2024-09-11 | C4 Therapeutics, Inc. | Spirocyclic degronimers for target protein degradation |
| EP3455218A4 (en) | 2016-05-10 | 2019-12-18 | C4 Therapeutics, Inc. | C3 CARBON-BASED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN REDUCTION |
| US10899788B2 (en) | 2016-06-20 | 2021-01-26 | Merck Sharp & Dohme Corp. | Cyclic phosphate substituted nucleoside compounds and methods of use thereof for the treatment of viral diseases |
| WO2018044986A1 (en) * | 2016-08-30 | 2018-03-08 | The Rockefeller University | Triazinoindole-based chemical inhibitors of eukaryotic ribosome biogenesis |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE648639C (de) | 1935-05-19 | 1937-08-05 | I G Farbenindustrie Akt Ges | Verfahren zur Darstellung von Dipyrrolen |
| US3404157A (en) * | 1965-02-24 | 1968-10-01 | American Cyanamid Co | Substituted pyrroloindazole compounds |
| US3632805A (en) | 1967-12-08 | 1972-01-04 | Sumitomo Chemical Co | Process for producing 1-aminoalkyl-benzodiazepine derivatives |
| US3631057A (en) * | 1970-01-06 | 1971-12-28 | American Cyanamid Co | Novel 4 7 - dimethyl-6-(lower alkyl) isoxazolo(5 4-e)indoles and methods of preparing same |
| AU575854B2 (en) | 1983-10-04 | 1988-08-11 | Shionogi & Co., Ltd. | 7beta-(carboxyalkenamido) cephalosporins |
| US5017380A (en) | 1986-07-02 | 1991-05-21 | Shionogi & Co., Ltd. | Gelatin hard capsule containing crystalline hydrate of oral cephalosporin |
| NZ220764A (en) | 1986-07-02 | 1989-09-27 | Shionogi & Co | Crystalline form of 7beta((z)-2-(2-aminothiazol-4-yl)-4- carboxybut-2-enoylamino)-3-cephem-4-carboxylic acid and pharmaceutical compositions |
| CA2038925A1 (en) | 1990-03-26 | 1991-09-27 | Takashi Sohda | Indole derivatives, their production and use |
| JPH04149429A (ja) | 1990-10-12 | 1992-05-22 | Fuji Photo Film Co Ltd | ハロゲン化銀カラー反転写真感光材料およびそれを用いた画像形成方法 |
| IT1278077B1 (it) | 1995-05-25 | 1997-11-17 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal |
| US5922757A (en) | 1996-09-30 | 1999-07-13 | The Regents Of The University Of California | Treatment and prevention of hepatic disorders |
| EE04023B1 (et) | 1996-10-18 | 2003-04-15 | Vertex Pharmaceuticals Incorporated | Seriinproteaaside, eriti C-hepatiidi viiruse NS3-proteaasi inhibiitorid |
| GB9623908D0 (en) | 1996-11-18 | 1997-01-08 | Hoffmann La Roche | Amino acid derivatives |
| AU757072B2 (en) | 1997-08-11 | 2003-01-30 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C inhibitor peptide analogues |
| FR2768146B1 (fr) | 1997-09-05 | 2000-05-05 | Oreal | Nouveaux composes de la famille des indole-carboxyliques et leur utilisation |
| DE60137207D1 (de) | 2000-04-05 | 2009-02-12 | Schering Corp | Makrozyklische inhibitoren der ns3-serinprotease des hepatitis c-virus mit stickstoffhaltigen zyklischen p2-gruppen |
| RU2002131163A (ru) | 2000-04-19 | 2004-06-27 | Шеринг Корпорейшн (US) | Макроциклические ингибиторы ns3-серинпротезы вируса гепатита с, содержащие алкил- и арилаланиновые p2 фрагменты |
| AR029851A1 (es) | 2000-07-21 | 2003-07-16 | Dendreon Corp | Nuevos peptidos como inhibidores de ns3-serina proteasa del virus de hepatitis c |
| ES2341534T3 (es) | 2000-07-21 | 2010-06-22 | Schering Corporation | Peptidos como inhibidores de la serina proteasa ns3 del virus de la hepatitis c. |
| EP1303487A4 (en) | 2000-07-21 | 2005-11-23 | Schering Corp | NOVEL PEPTIDES AS INHIBITORS OF THE NS3 SERINE PROTEASE OF HEPATITIS C VIRUS |
| AR034127A1 (es) | 2000-07-21 | 2004-02-04 | Schering Corp | Imidazolidinonas como inhibidores de ns3-serina proteasa del virus de hepatitis c, composicion farmaceutica, un metodo para su preparacion, y el uso de las mismas para la manufactura de un medicamento |
| EP1341761A1 (en) | 2000-10-10 | 2003-09-10 | Smithkline Beecham Corporation | SUBSTITUTED INDOLES, PHARMACEUTICAL COMPOSITIONS CONTAINING SUCH INDOLES AND THEIR USE AS PPAR-$g(g) BINDING AGENTS |
| JP4368581B2 (ja) | 2000-12-12 | 2009-11-18 | シェーリング コーポレイション | Ｃ型肝炎ウイルスのｎｓ３−セリンプロテアーゼ阻害剤としてのジアリールペプチド |
| JP2004518658A (ja) | 2000-12-18 | 2004-06-24 | イーライ・リリー・アンド・カンパニー | 新規なｓＰＬＡ２インヒビター |
| ATE378328T1 (de) * | 2001-02-22 | 2007-11-15 | Univ London Pharmacy | Pyrrolo-indol- und pyrrolo-chinolin-derivate als prodrugs zur tumorbehandlung |
| EP2335700A1 (en) | 2001-07-25 | 2011-06-22 | Boehringer Ingelheim (Canada) Ltd. | Hepatitis C virus polymerase inhibitors with a heterobicylic structure |
| US20050215614A1 (en) * | 2002-10-15 | 2005-09-29 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| US20050075331A1 (en) | 2003-10-06 | 2005-04-07 | Pratt John K. | Anti-infective agents |
| ES2382377T3 (es) * | 2003-05-30 | 2012-06-07 | Gemin X Pharmaceuticals Canada Inc. | Compuestos triheterocíclicos, composiciones, y métodos para tratar cáncer |
| GB0323845D0 (en) | 2003-10-10 | 2003-11-12 | Angeletti P Ist Richerche Bio | Chemical compounds,compositions and uses |
| WO2005047324A2 (en) | 2003-11-10 | 2005-05-26 | Schering Corp | ANTI-INTERLEUKIN ANTIBODY-10 |
| NZ549223A (en) | 2004-02-27 | 2010-10-29 | Schering Corp | Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease |
| WO2005084315A2 (en) | 2004-03-01 | 2005-09-15 | Viropharma Incorporated | Pyranoindole derivatives and the use thereof for the treatment of hepatitis c virus infection or disease |
| PE20060309A1 (es) | 2004-05-06 | 2006-04-13 | Schering Corp | (1r,2s,5s)-n-[(1s)-3-amino-1-(ciclobutilmetil)-2,3-dioxopropil]-3-[(2s)-2[[[(1,1-dimetiletil)amino]carbonil]amino]-3,3-dimetil-1-oxobutil]-6,6-dimetil-3-azabiciclo[3.1.o]hexan-2-carboxamida como inhibidor de la ns3/ns4a serina proteasa del virus de l |
| EP1604988A1 (en) | 2004-05-18 | 2005-12-14 | Sanofi-Aventis Deutschland GmbH | Pyridazinone derivatives, methods for producing them and their use as pharmaceuticals |
| WO2007084413A2 (en) | 2004-07-14 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| CN101035528A (zh) | 2004-09-23 | 2007-09-12 | 惠氏公司 | 治疗丙型肝炎病毒感染的咔唑和环戊二烯并吲哚衍生物 |
| DE102004047272A1 (de) | 2004-09-24 | 2006-04-06 | Schering Ag | Inhibitoren der löslichen Adenylatzyklase |
| JP4149429B2 (ja) | 2004-10-26 | 2008-09-10 | 本田技研工業株式会社 | 車両の走行安全装置 |
| CA2585084A1 (en) | 2004-10-26 | 2006-05-04 | Immacolata Conte | Tetracyclic indole derivatives as antiviral agents |
| MX2007008587A (es) | 2005-01-14 | 2007-09-07 | Genelabs Tech Inc | Derivados de indol para tratamiento de infecciones virales. |
| US20110104109A1 (en) | 2005-07-13 | 2011-05-05 | Frank Bennett | Tetracyclic indole derivatives and their use for treating or preventing viral infections |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| EP1940850A2 (en) | 2005-09-23 | 2008-07-09 | Schering Corporation | Fused tetracyclic mglur1 antagonists as therapeutic agents |
| WO2007084435A2 (en) | 2006-01-13 | 2007-07-26 | Ptc Therapeutics, Inc. | Methods for treating hepatitis c |
| US20070274951A1 (en) | 2006-02-09 | 2007-11-29 | Xiao Tong | Combinations comprising HCV protease inhibitor(s) and HCV polymerase inhibitor(s), and methods of treatment related thereto |
| MX2009006877A (es) | 2006-12-22 | 2009-09-28 | Schering Corp | Derivados indolicos con anillo unido en las posiciones 5,6 y metodos de uso de los mismos. |
| EP2064180B1 (en) | 2006-12-22 | 2016-07-13 | Merck Sharp & Dohme Corp. | 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| EP2064181A1 (en) | 2006-12-22 | 2009-06-03 | Schering Corporation | 4, 5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections |
| CN101842374A (zh) | 2007-08-29 | 2010-09-22 | 先灵公司 | 用于治疗病毒感染的2，3-取代的氮杂吲哚衍生物 |
| AU2008295484B2 (en) | 2007-08-29 | 2013-09-26 | Merck Sharp & Dohme Llc | Substituted indole derivatives and methods of use thereof |
| EP2197842B1 (en) | 2007-08-29 | 2012-05-23 | Schering Corporation | 2, 3-substituted indole derivatives for treating viral infections |
| US8765757B2 (en) | 2007-11-16 | 2014-07-01 | Merck Sharp & Dohme Corp. | 3-heterocyclic substituted indole derivatives and methods of use thereof |
| CN102317285A (zh) | 2007-11-16 | 2012-01-11 | 先灵公司 | 3-氨基磺酰基取代的吲哚衍生物及其使用方法 |
| CA2727620A1 (en) | 2008-06-13 | 2009-12-17 | Schering Corporation | Tricyclic indole derivatives and methods of use thereof |
-
2007
- 2007-12-17 EP EP07862998.7A patent/EP2064180B1/en active Active
- 2007-12-17 CA CA2673249A patent/CA2673249C/en active Active
- 2007-12-17 AU AU2007339382A patent/AU2007339382B2/en not_active Ceased
- 2007-12-17 KR KR1020097015298A patent/KR20090094154A/ko not_active Application Discontinuation
- 2007-12-17 JP JP2009542835A patent/JP5079818B2/ja not_active Expired - Fee Related
- 2007-12-17 BR BRPI0720625-9A2A patent/BRPI0720625A2/pt not_active Application Discontinuation
- 2007-12-17 CN CN200780051419A patent/CN101631773A/zh active Pending
- 2007-12-17 RU RU2009127855/04A patent/RU2009127855A/ru not_active Application Discontinuation
- 2007-12-17 US US12/519,715 patent/US8557848B2/en active Active
- 2007-12-17 WO PCT/US2007/025754 patent/WO2008082484A1/en active Application Filing
- 2007-12-17 MX MX2009006880A patent/MX2009006880A/es unknown
- 2007-12-18 AR ARP070105705A patent/AR064428A1/es not_active Application Discontinuation
- 2007-12-18 TW TW096148504A patent/TW200831496A/zh unknown
- 2007-12-18 CL CL200703686A patent/CL2007003686A1/es unknown
-
2008
- 2008-01-02 PE PE2008000053A patent/PE20081608A1/es not_active Application Discontinuation
-
2009
- 2009-06-18 CO CO09063496A patent/CO6190515A2/es not_active Application Discontinuation
- 2009-06-19 EC EC2009009447A patent/ECSP099447A/es unknown
- 2009-07-21 NO NO20092742A patent/NO20092742L/no not_active Application Discontinuation
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2011524359A (ja) * | 2008-06-13 | 2011-09-01 | シェーリング コーポレイション | ３環式インドール誘導体およびその使用方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| JP2010513490A (ja) | 2010-04-30 |
| PE20081608A1 (es) | 2008-11-12 |
| US8557848B2 (en) | 2013-10-15 |
| AU2007339382B2 (en) | 2013-05-02 |
| CA2673249C (en) | 2013-04-30 |
| KR20090094154A (ko) | 2009-09-03 |
| MX2009006880A (es) | 2009-07-03 |
| RU2009127855A (ru) | 2011-01-27 |
| WO2008082484A1 (en) | 2008-07-10 |
| EP2064180B1 (en) | 2016-07-13 |
| CN101631773A (zh) | 2010-01-20 |
| US20100098661A1 (en) | 2010-04-22 |
| CO6190515A2 (es) | 2010-08-19 |
| EP2064180A1 (en) | 2009-06-03 |
| BRPI0720625A2 (pt) | 2014-03-25 |
| CL2007003686A1 (es) | 2008-06-27 |
| ECSP099447A (es) | 2009-07-31 |
| CA2673249A1 (en) | 2008-07-10 |
| AU2007339382A1 (en) | 2008-07-10 |
| NO20092742L (no) | 2009-09-21 |
| TW200831496A (en) | 2008-08-01 |
| AR064428A1 (es) | 2009-04-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5079818B2 (ja) | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 | |
| JP5211068B2 (ja) | Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体 | |
| JP5055377B2 (ja) | ［５，６−環］環形成インドール誘導体およびその使用方法 | |
| JP5179585B2 (ja) | 四環系インドール誘導体およびその使用法 | |
| JP5272008B2 (ja) | 置換インドール誘導体およびその使用の方法 | |
| JP5258889B2 (ja) | ウイルス感染症の治療のための２，３−置換アザインドール誘導体 | |
| JP5249344B2 (ja) | ヘテロ環の３位が置換されたインドール誘導体およびその使用 | |
| JP5416708B2 (ja) | ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法 | |
| US20110104109A1 (en) | Tetracyclic indole derivatives and their use for treating or preventing viral infections | |
| JP5580814B2 (ja) | ３環式インドール誘導体およびその使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100813 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20120424 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120501 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120727 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120817 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20120829 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5079818 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20150907 Year of fee payment: 3 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| LAPS | Cancellation because of no payment of annual fees |